Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.
Frequently asked questions
What sector does Medigen Vaccine Biologics (6547) operate in?
Medigen Vaccine Biologics belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Medigen Vaccine Biologics (6547) current stock price?
As of the latest data, Medigen Vaccine Biologics stock price is NT$61.10, with a previous close of NT$59.80. Medigen Vaccine Biologics gained NT$1.30 in the last trading session, representing a 2.17% increase.
What is Medigen Vaccine Biologics (6547) current market capitalization?
Medigen Vaccine Biologics market cap is approximately 20.09 billion.
What is Medigen Vaccine Biologics (6547) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.51, and the forward EPS is NT$1.46.
Does Medigen Vaccine Biologics (6547) pay dividends?
No. Medigen Vaccine Biologics does not pay a dividend.
How did Medigen Vaccine Biologics (6547) perform in its most recent earnings report?
In the last report (June 30, 2026), Medigen Vaccine Biologics posted an EPS surprise of -400% and a revenue surprise of -39.47%.
What is Medigen Vaccine Biologics (6547) beta (volatility) score?
Medigen Vaccine Biologics has a beta of -0.060, indicating lower volatility than the overall market.
